Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study

Mother-to-child transmission sustains the burden of hepatitis B virus (HBV) infection in sub-Saharan Africa, yet little is known about whether women giving birth in Uganda are protected. We estimated the prevalence of protective hepatitis B surface antibody (anti-HBs) levels, described serological profiles and identified associated factors among women admitted for delivery at Kawempe National Referral Hospital, Kampala. In this cross-sectional study, 418 women were selected by systematic random sampling in 2024 and interviewed about socio-demographic characteristics, hepatitis B testing, vaccination and exposures. Anti-HBs was quantified by electrochemiluminescence immunoassay (protective: ≥10 mIU/mL); other HBV markers were screened with a rapid test. Prevalence ratios were estimated with modified Poisson regression. Overall, 264 women (63.2%) reported vaccination: 203 during the current pregnancy and 61 before it only. Protective levels were found in 322 women (77.0%; 95% confidence interval [CI] 72.8–80.8): 50.6% of never-vaccinated women, 82.0% of those vaccinated before the current pregnancy only and 95.6% of those vaccinated during it. After adjustment, vaccination before the current pregnancy only (adjusted prevalence ratio 1.54; 95% CI 1.24–1.89) and during it (1.86; 95% CI 1.57–2.20) were associated with protection; no socio-demographic or behavioural factor was. Eighty-two women (19.6%) had no serological evidence of immunity or infection; 65 had never been vaccinated. Of 300 women who reported a previous negative test, 50 (16.7%) had never been vaccinated, and 68 of 250 vaccinated women with known completion status (27.2%) had not completed three doses, mostly because they were not told to return or forgot. The rapid test detected hepatitis B surface antigen in 21 women (5.0%), but discordant marker patterns suggest some false positives. One in five women reached delivery susceptible to HBV, largely because a negative test was not followed by vaccination. Linking every negative antenatal test to vaccination could close much of this gap.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.26367773
Primary Topic
Hepatitis B Virus Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study

Emilly Kembabazi, Moses Ocan, HOOD IBANDA
medRxiv
Hepatitis B Virus Studies
preprint

Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study

Emilly Kembabazi, Moses Ocan, HOOD IBANDA
preprint en

Abstract

Mother-to-child transmission sustains the burden of hepatitis B virus (HBV) infection in sub-Saharan Africa, yet little is known about whether women giving birth in Uganda are protected. We estimated the prevalence of protective hepatitis B surface antibody (anti-HBs) levels, described serological profiles and identified associated factors among women admitted for delivery at Kawempe National Referral Hospital, Kampala. In this cross-sectional study, 418 women were selected by systematic random sampling in 2024 and interviewed about socio-demographic characteristics, hepatitis B testing, vaccination and exposures. Anti-HBs was quantified by electrochemiluminescence immunoassay (protective: ≥10 mIU/mL); other HBV markers were screened with a rapid test. Prevalence ratios were estimated with modified Poisson regression. Overall, 264 women (63.2%) reported vaccination: 203 during the current pregnancy and 61 before it only. Protective levels were found in 322 women (77.0%; 95% confidence interval [CI] 72.8–80.8): 50.6% of never-vaccinated women, 82.0% of those vaccinated before the current pregnancy only and 95.6% of those vaccinated during it. After adjustment, vaccination before the current pregnancy only (adjusted prevalence ratio 1.54; 95% CI 1.24–1.89) and during it (1.86; 95% CI 1.57–2.20) were associated with protection; no socio-demographic or behavioural factor was. Eighty-two women (19.6%) had no serological evidence of immunity or infection; 65 had never been vaccinated. Of 300 women who reported a previous negative test, 50 (16.7%) had never been vaccinated, and 68 of 250 vaccinated women with known completion status (27.2%) had not completed three doses, mostly because they were not told to return or forgot. The rapid test detected hepatitis B surface antigen in 21 women (5.0%), but discordant marker patterns suggest some false positives. One in five women reached delivery susceptible to HBV, largely because a negative test was not followed by vaccination. Linking every negative antenatal test to vaccination could close much of this gap.

medRxiv
Makerere University (UG)
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon